Revance Therapeutics/RVNC

$3.14

-0.63%
-
1D1W1MYTD1YMAX

About Revance Therapeutics

Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.

Ticker

RVNC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mark Foley

Employees

534

Headquarters

Nashville, United States

RVNC Metrics

BasicAdvanced
$346M
Market cap
-
P/E ratio
-$3.65
EPS
1.07
Beta
-
Dividend rate
$346M
1.06926
$33.71
$3.00
2M
5.365
4.636
-30.79%
-59.42%
-69.02%
1.461
54.59%
19.1%
148.1%

What the Analysts think about RVNC

Analyst Ratings

Majority rating from 12 analysts.
Buy

Price Targets

Average projection from 11 analysts.
311.15% upside
High $25.00
Low $6.00
$3.14
Current price
$12.91
Average price target

RVNC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-102.31% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$52M
-25.54%
Net income
-$53M
-4.5%
Profit margin
-102.31%
28.26%

RVNC Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 22.67%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.80
-$1.63
-$0.62
-$0.58
-
Expected
-$0.78
-$0.85
-$0.72
-$0.75
-$0.53
Surprise
2.86%
91.09%
-14.38%
-22.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Revance Therapeutics stock?

Revance Therapeutics (RVNC) has a market cap of $315M as of May 20, 2024.

What is the P/E ratio for Revance Therapeutics stock?

The price to earnings (P/E) ratio for Revance Therapeutics (RVNC) stock is 0 as of May 20, 2024.

Does Revance Therapeutics stock pay dividends?

No, Revance Therapeutics (RVNC) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Revance Therapeutics dividend payment date?

Revance Therapeutics (RVNC) stock does not pay dividends to its shareholders.

What is the beta indicator for Revance Therapeutics?

Revance Therapeutics (RVNC) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Revance Therapeutics stock price target?

The target price for Revance Therapeutics (RVNC) stock is $12.91, which is 327.48% above the current price of $3.02. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Revance Therapeutics stock

Buy or sell Revance Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing